RxDoctor Payments Data

Sherrlyn McFadden, NP

Family · Olanta, SCNPI 1154789220

Payments from drug & device makers

$2,461in general payments, 2019–2025

Across 134 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$388
  • Novartis$329
  • Novo Nordisk$308
  • Abbott$266
  • Amarin Pharma, Inc.$237
  • Bayer$181
  • plus $752 from 13 others

What the payments were for

  • Food & beverage$2,461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,461 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$3,121
Medicare patients
40
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab34$22,515
MounjaroTirzepatide18$21,422
OzempicSemaglutide13$19,691
LipitorAtorvastatin Calcium16$16,368
NorvascAmlodipine Besylate16$9,028
CrestorRosuvastatin Calcium14$8,673
ArexvyRsvpref3 Antigen/As01e/Pf19$5,267
Tresiba Flextouch U-200Insulin Degludec11$2,808
Lidocaine14$701
Rosuvastatin Calcium17$569
Albuterol Sulfate HfaAlbuterol Sulfate21$475
Fluticasone Propionate28$298
Potassium Chloride16$215
Prednisone39$141
Cyclobenzaprine Hcl17$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$28$21,42218 claims
Novo NordiskOzempic$308$19,69113 claims
AstraZenecaCrestor$29$8,67314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Olanta

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →